AGENUS INC - 8-K Filing
Agenus Inc. reported first-quarter 2026 financial results on May 11, 2026, showing total revenue of $33.7 million and a net income of $39.2 million as cash balances rose to $35.0 million by March 31, 2026. The company highlighted progress in its lead program botensilimab plus balstilimab (BOT+BAL), including the start of Phase 3 BATTMAN trial enrollment and a Zydus collaboration that provided $91 million upfront capital and secured U.S. manufacturing capacity. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $AGEN